Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 154-158 , Summer 2009

Current Options for Systemic Therapy in Mesothelioma

  • David M. Jackman, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to David M. Jackman, MD, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115

References 

  1. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus, and Heart. Lyon: IARC; 2004;
  2. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55:731–735
  3. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723–731
  4. van Klaveren RJ, Aerts JG, de Bruin H, et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer. 2004;43:63–69
  5. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–260
  6. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet. 2008;371:1685–1694
  7. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura (A phase II study). Br J Cancer. 1992;65:956–960
  8. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-Z]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–1123
  9. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-Z]pyrimidine-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem. 1992;35:4450–4454
  10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  11. Santoro A, O'Brien ME, Stahel R, et al. Pemetrexed plus cisplatin (P+ Cis) or pemetrexed plus carboplatin (P+ Cb) for chemonaive patients with malignant pleural mesothelioma (MPM): Results of the international expanded Access Program (EAP). J Clin Oncol. 2007;25:7562
  12. Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: Results of an international expanded access program. J Thorac Oncol. 2008;3:764–771
  13. Janne PA, Wozniak AJ, Belani CP, et al. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: Outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506–512
  14. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol. 2008;26:1698–1704
  15. van den Bogaert DP, Pouw EM, van Wijhe G, et al. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2006;1:25–30
  16. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol. 1998;17:A464;(abstract 1784)
  17. Kindler HL, Millard F, Herndon JE, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001;31:311–317
  18. van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma (European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group). Cancer. 1999;85:2577–2582
  19. Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. Am J Clin Oncol. 2005;28:223–226
  20. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer. 2008;60:259–263
  21. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491–496
  22. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II trial. J Clin Oncol. 1999;17:25–30
  23. van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86:342–345
  24. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma (MM). Proc Am Soc Clin Oncol. 2007;18:S391;(abstract 7526)
  25. Ryad AY, Mostafa E, Salem DA, et al. Assessment of survival and clinical benefit in malignant pleural mesothelioma (MPM) patients treated with gemcitabine and carboplatin. J Egypt Natl Cancer Inst. 2007;19:61–70
  26. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: A multicentric phase II study. Cancer. 2003;97:2791–2797
  27. Lee CW, Murray N, Anderson H, et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer. 2009;64:308–313
  28. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63:94–97
  29. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer. 2008;99:44–50
  30. Lerner HJ, Schoenfeld DA, Martin A, et al: Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981-1985v
  31. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep. 1985;69:1431–1432
  32. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: A phase II cooperative study (The North-Eastern Italian Oncology Group (GOCCNE)—Mesothelioma Committee). Tumori. 1991;77:49–51
  33. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1992;10:824–828
  34. Konig J, Tolnay E, Wiethege T, et al. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration. 2000;67:36–40
  35. Konig JE, Tolnay E, Wiethege T, et al. Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch. 1999;435:8–12
  36. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193:468–475
  37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  38. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  39. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666622676
  40. Jahan TM, Gu L, Wang X, et al. Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol. 2006;24(suppl):(abstract 7081)
  41. Janne PA, Wang EF, Krug LM, et al. Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307). J Clin Oncol. 2007;25(suppl):3936;(abstract 7707)
  42. Nowak AK, Millward MJ, Francis R, et al. Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol. 2008;26:S439;(abstract 8063)
  43. Dazzi H, Hasleton PS, Thatcher N, et al. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R) (Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody). Br J Cancer. 1990;61:924–926
  44. Govindan R, Suppiah R, Ritter J. EGFR and Her-2 overexpression in malignant mesothelioma. Proc Am Soc Clin Oncol. 2001;20:3106;(abstract)
  45. Govindan R, Kratzke RA, Herndon JE, et al. Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005;11:2300–2304
  46. Janne PA, Taffaro ML, Salgia R, et al. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002;62:5242–5247
  47. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study. J Clin Oncol. 2007;25:2406–2413
  48. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113:808–814
  49. Coffey DC, Kutko MC, Glick RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol. 2000;35:577–581
  50. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210–1216
  51. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014–10019
  52. Krug LM, Curley T, Schwartz L, et al. Potential role of histone deacetylase inhibitors in mesothelioma: Clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer. 2006;7:257–261
  53. http://www.clinicaltrials.gov/ct2/show/NCT00128102?term=vorinostat+and+mesothelioma&rank=1. Accessed: May 9, 2009
  54. Lee I, Kalota A, Gewirtz AM, et al. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 2007;27(1A):299–307
  55. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002;20:274–281
  56. Vogelzang NJ, Taub RN, Shin D, et al. Phase III randomized trial of Onconase (onc) vs doxorubicin (DOX) in patients with unresectable malignant mesothelioma (UMM): Analysis of survival. Proc Am Soc Clin Oncol. 2000;19:A577;(abstract 2274)
  57. Press release, AlfaCell May 28, 2008
  58. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136–140
  59. Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of Morab-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20
  60. Quian L, Verschraegen CF, Mendoza J, et al. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res. 2009;(in press)
  61. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008;44:46–53
  62. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004;200:297–306
  63. Tsao AS, He DD, Saigal B, et al. Activated Src inase is expressed in malignant pleural mesothelioma tumors; dasatainib inhibition leads to cytotoxicity, cell cycle inhibition, and prevention of invasion and migration. Proc Am Soc Clin Oncol. 1998;(abstract 1784)

 This work was supported by the Alice and Stephen D. Cutler Investigator Fund in Thoracic Oncology at Dana-Farber Cancer Institute.

 Dr. Jackman has served on an advisory board to Genentech and has received honoraria from Roche.

PII: S1043-0679(09)00074-4

doi: 10.1053/j.semtcvs.2009.06.010

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 154-158 , Summer 2009

Article Tools